A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)
RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : lestaurtinib
Phase: Phase 1
Ages Eligible For Study: